Olivier Bylicki

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 6

Top Topics

Mesenchymal Stem Cells

Small Cell Lung Cancer

Epidermal Growth Factor Receptor

Top Venues

OncoTargets and therapy

Cancer management and research

Current oncology (Toronto, Ont.)

Targeted oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Sébastien Gendarme, Olivier Bylicki, Christos Chouaid, Florian Guisier
ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date. Current oncology (Toronto, Ont.) 29 (2) (2022)
Olivier Bylicki, Nicolas Paleiron, Jean-Baptiste Assié, Christos Chouaïd
Targeting the MET-Signaling Pathway in Non-Small-Cell Lung Cancer: Evidence to Date. OncoTargets and therapy 13 (2020)
Olivier Bylicki, Morgane Didier, Frederic Riviere, Jacques Margery, Frederic Grassin, Christos Chouaid
Lung cancer and end-of-life care: a systematic review and thematic synthesis of aggressive inpatient care. BMJ supportive & palliative care 9 (4) (2019)
Alain Vergnenegre, Victor Basse, Gwenaelle Le Garff, Olivier Bylicki, Catherine Dubos-Arvis, Bénédicte Comet, Marie Marcq, Jacques Le Treut, Jean-Bernard Auliac, Anne Madroszyk, Gislaine Fraboulet, Jacky Crequit, Pascal Thomas, Nicolas Paleiron, Isabelle Monnet, null null
Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small-Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01). Cancer management and research 11 (2019)
Olivier Bylicki, Helene Barazzutti, Nicolas Paleiron, Jacques Margery, Jean-Baptiste Assié, Christos Chouaid
First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 33 (2) (2019)
Olivier Bylicki, Nicolas Paleiron, Jacques Margery, Florian Guisier, Alain Vergnenegre, Gilles Robinet, Jean-Bernard Auliac, Radj Gervais, Christos Chouaid
Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer. Targeted oncology 12 (5) (2018)